Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Friday the receipt of the US FDA approval for the generic version of BiCNU (carmustine) for injection in 100 mg.
In conjunction, the company plans to launch its Carmustine for Injection in November 2018. Carmustine is a medication used mainly for chemotherapy.
For the 12 months ended August 2018, the US market annual sales for Carmustine for Injection USP in 100 mg/vial is estimated to be about USD84m, according to IQVIA.
Headquartered in Bridgewater, NJ, the specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval